Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 in Pheochromocytoma, Paraganglioma, or Non-functioning Carcinoid
NCT01152827Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in pheochromocytoma, extra-adrenal paraganglioma (PGL) and Carcinoid Tumor (CT), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival Rate at 4 months. Started Jul 2008; status: completed.
02
Drugs
everolimus
03
Conditions
pheochromocytomaextra-adrenal paraganglioma (PGL)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT01152827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152827.